Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences (RNA) Invested Capital (2019 - 2025)

Historic Invested Capital for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $1.9 billion.

  • Avidity Biosciences' Invested Capital rose 2546.83% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 2546.83%. This contributed to the annual value of $1.4 billion for FY2024, which is 18455.7% up from last year.
  • Avidity Biosciences' Invested Capital amounted to $1.9 billion in Q3 2025, which was up 2546.83% from $1.2 billion recorded in Q2 2025.
  • Avidity Biosciences' 5-year Invested Capital high stood at $1.9 billion for Q3 2025, and its period low was $264.5 million during Q2 2021.
  • Over the past 5 years, Avidity Biosciences' median Invested Capital value was $558.9 million (recorded in 2023), while the average stood at $766.1 million.
  • As far as peak fluctuations go, Avidity Biosciences' Invested Capital tumbled by 1992.64% in 2021, and later surged by 19052.62% in 2024.
  • Quarter analysis of 5 years shows Avidity Biosciences' Invested Capital stood at $381.4 million in 2021, then soared by 51.55% to $578.1 million in 2022, then decreased by 13.37% to $500.8 million in 2023, then skyrocketed by 184.56% to $1.4 billion in 2024, then skyrocketed by 32.37% to $1.9 billion in 2025.
  • Its last three reported values are $1.9 billion in Q3 2025, $1.2 billion for Q2 2025, and $1.3 billion during Q1 2025.